AltPep secures FDA breakthrough device designation

2019 05 13 16 12 9218 Lab Blood Woman2 400

AltPep's Soba-AD blood test for detecting biomarkers related to Alzheimer's disease has garnered breakthrough designation from the U.S. Food and Drug Administration (FDA).

Soba-AD is designed to selectively detect toxic oligomers that trigger events associated with Alzheimer's disease such as cognitive impairment and neurodegeneration, according to the company. The goal is to detect the early molecular triggers of the disease before plaque formation, AltPep Founder and CEO Valerie Daggett, PhD, said.

Page 1 of 5
Next Page